The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Targeting the protein kinase C family: are we there yet?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472
Ranade, V. V. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817c941f · Cited by 2,775
Protein Kinase C: Structure, Function, and Regulation
Newton, A. C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28495 · Cited by 1,655
Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976
Martiny-Baron, G., Kazanietz, M. G., Mischak, H., Blumberg, P. M., Kochs, G., Hug, H., Marmé, D., & Schächtele, C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98335-3 · Cited by 1,565
Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids.
Takai, Y., Kishimoto, A., Iwasa, Y., Kawahara, Y., Mori, T., & Nishizuka, Y. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50638-4 · Cited by 1,138
Protein Kinase C δ Activates the MEK-ERK Pathway in a Manner Independent of Ras and Dependent on Raf
Ueda, Y., Hirai, S.-I., Osada, S.-I., Suzuki, A., Mizuno, K., & Ohno, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23512 · Cited by 572
Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119006 · Cited by 566
Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C
Wilkinson, S. E., Parker, P. J., & Nixon, J. S. (1993) · Biochemical Journal · doi:10.1042/bj2940335 · Cited by 522
Inhibition of protein kinase C by tamoxifen.
O'Brian, C. A., Liskamp, R. M. J., Solomon, D. H., & Weinstein, I. B. (1985) · PubMed · Cited by 461
Ruvolo, P. P., Deng, X., Carr, B. K., & May, W. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25436 · Cited by 452
Graff, J. R., McNulty, A. M., Hanna, K. R., Konicek, B. W., Lynch, R. L., Bailey, S. N., Banks, C., Capen, A., Goode, R., Lewis, J. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0071 · Cited by 442
Identification of PKC-isoform-specific biological actions using pharmacological approaches
Way, K. J., Chou, E., & King, G. L. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01468-1 · Cited by 435
Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes.
Goode, N., Hughes, K., Woodgett, J. R., & Parker, P. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41866-2 · Cited by 396
Localization of Protein Kinase C Isozymes in Cardiac Myocytes
Disatnik, M.-H., Buraggi, G., & Mochly-Rosen, D. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1041 · Cited by 333
Vang, T., Torgersen, K. M., Sundvold, V., Saxena, M., Levy, F. O., Skålhegg, B. S., Hansson, V., Mustelin, T., & Taskén, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.497 · Cited by 330
Dean, N. M., McKay, R., Condon, T. P., & Bennett, C. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34023-1 · Cited by 291
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
Cai, H., Smola, U., Wixler, V., Eisenmann-Tappe, I., Diaz-Meco, M. T., Moscat, J., Rapp, U., & Cooper, G. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.732 · Cited by 291
Ways, D. K., Kukoly, C. A., deVente, J., Hooker, J. L., Bryant, W. O., Posekany, K. J., Fletcher, D. J., Cook, P. P., & Parker, P. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117872 · Cited by 266
Ceramide Inactivates Cellular Protein Kinase Cα
Lee, J. Y., Hannun, Y. A., & Obeid, L. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13169 · Cited by 259
Regulation of protein kinase C and role in cancer biology
Blobe, G. C., Obeid, L. M., & Hannun, Y. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00666107 · Cited by 255
Hocevar, B. A., & Fields, A. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52396-6 · Cited by 247
Szallasi, Z., Smith, C. B., Pettit, G. R., & Blumberg, P. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42143-0 · Cited by 240
Phorbol esters induce multidrug resistance in human breast cancer cells.
Fine, R. L., Patel, J., & Chabner, B. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.2.582 · Cited by 238
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1485 · Cited by 233
Self-citationSignal perception and transduction: the role of protein kinases
Schenk, P. W., & Snaar-Jagalska, B. E. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(98)00178-5 · Cited by 231
Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R., & Yuspa, S. H. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1343 · Cited by 230
Shapira, L., Takashiba, S., Champagne, C., Amar, S., & Van Dyke, T. E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1818 · Cited by 222
(1996) · PubMed · Cited by 221
PKC-δ is an apoptotic lamin kinase
Cross, T., Griffiths, G., Deacon, E., Sallis, R., Gough, M., Watters, D., & Lord, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203555 · Cited by 216
O'Brian, C. A., Vogel, V. G., Singletary, S. E., & Ward, N. E. (1989) · PubMed · Cited by 214
Balendran, A., Hare, G. R., Kieloch, A., Williams, M. R., & Alessi, D. R. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02162-1 · Cited by 210
Murray, N. R., Baumgardner, G. P., Burns, D. J., & Fields, A. P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82331-6 · Cited by 202
Identification of nuclear beta II protein kinase C as a mitotic lamin kinase.
Goss, V. L., Hocevar, B. A., Thompson, L. J., Stratton, C. A., Burns, D. J., & Fields, A. P. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32276-7 · Cited by 200
Norris, J. G., Tang, L. P., Sparacio, S. M., & Benveniste, E. N. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.2.841 · Cited by 193
Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S. A., Rockett, H., Talbot, D. C., Ganesan, T., Pettit, G. R., Balkwill, F., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.22.1812 · Cited by 187
Mandil, R., Ashkenazi, E., Blass, M., Kronfeld, I., Kazimirsky, G., Rosenthal, G., Umansky, F., Lorenzo, P. S., Blumberg, P. M., & Brodie, C. (2001) · PubMed · Cited by 184
Murray, N. R., Davidson, L. A., Chapkin, R. S., Clay Gustafson, W., Schattenberg, D. G., & Fields, A. P. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.4.699 · Cited by 181
Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.
Gökmen‐Polar, Y., Murray, N. R., Velasco, M. A. D., Gatalica, Z., & Fields, A. P. (2001) · PubMed · Cited by 180
Carducci, M. A., Musib, L., Kies, M. S., Pili, R., Truong, M., Brahmer, J. R., Cole, P., Sullivan, R., Riddle, J., Schmidt, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3447 · Cited by 176
Dean, N. S., McKay, R. A., Miraglia, L. J., Howard, R., Cooper, S. R., Giddings, J., Nicklin, P. L., Meister, L., Ziel, R., Geiger, T. M., et al. (1996) · PubMed · Cited by 175
Fang, X., Yu, S., Tanyi, J. L., Lu, Y., Woodgett, J. R., & Mills, G. B. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2099-2110.2002 · Cited by 173
Nemunaitis, J., Holmlund, J. T., Kraynak, M., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Geary, R., Dorr, A., Von Hoff, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3586 · Cited by 173
Germann, U. A., Chambers, T. C., Ambudkar, S. V., Licht, T., Cardarelli, C. O., Pastan, I., & Gottesman, M. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.3.1708 · Cited by 172
Kawakami, Y., Nishimoto, H., Kitaura, J., Maeda-Yamamoto, M., Kato, R. M., Littman, D. R., Rawlings, D. J., & Kawakami, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408797200 · Cited by 166
Ubiquitination of Protein Kinase C-α and Degradation by the Proteasome
Lee, H.-W., Smith, L., Pettit, G. R., Vinitsky, A., & Smith, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.35.20973 · Cited by 163
Clark, A. S., West, K. A., Blumberg, P. M., & Dennis, P. A. (2003) · PubMed · Cited by 161
Paz-Ares, L. G., Douillard, J., Koralewski, P., Manegold, C., Smit, E. F., Reyes, J. M., Chang, G., John, W. J., Peterson, P. M., Obasaju, C. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3299 · Cited by 154
A phase I study of intravenous bryostatin 1 in patients with advanced cancer
Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A. T., Testa, N. G., Stern, P. L., McDermott, R. H., Potter, M., et al. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.352 · Cited by 146
Protein Kinase C Isoenzyme Patterns Characteristically Modulated in Early Prostate Cancer
Cornford, P. A., Evans, J., Dodson, A. R., PARSONS, K. F., Woolfenden, A., Neoptolemos, J. P., & Foster, C. S. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65260-1 · Cited by 144
Bryostatins: Potent, new mitogens that mimic phorbol ester tumor promoters
Smith, J. B., Smith, L., & Pettit, G. R. (1985) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(85)91898-4 · Cited by 137
Csukai, M., & Mochly‐Rosen, D. (1999) · Pharmacological Research · doi:10.1006/phrs.1998.0418 · Cited by 134
Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P. L., Young, R., Brenchley, P. E., Chang, J., Owens, S. E., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.356 · Cited by 125
Partovian, C., & Simons, M. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.01.008 · Cited by 123
Zhang, L., Huang, J., Yang, N., Liang, S., Barchetti, A., Giannakakis, A., Cadungog, M. G., O’Brien-Jenkins, A., Massobrio, M., Roby, K. F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4527 · Cited by 123
Goodfellow, H. R., Sardini, A., Ruetz, S., Callaghan, R., Gros, P., McNaughton, P. A., & Higgins, C. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13668 · Cited by 122
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice
Keyes, K. A., Mann, L. L., Sherman, M., Galbreath, E. J., Schirtzinger, L., Ballard, D. W., Chen, Y.-F., Iversen, P. W., & Teicher, B. A. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0713-x · Cited by 116
Kortmansky, J. S., Shah, M. A., Kaubisch, A., Weyerbacher, A. R., Yi, S., Tong, W. P., Sowers, R. S., Gönen, M., O'Reilly, E. M., Kemeny, N. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.116 · Cited by 112
Marshall, C. J. (1996) · Nature · doi:10.1038/383127a0 · Cited by 109
Protein kinase C: a target for anticancer drugs?
MacKay, H. J., & Twelves, C. J. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100389 · Cited by 104
Self-citationJane, E. P., Premkumar, D. R., & Pollack, I. F. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.108621 · Cited by 104
What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials
Adjei, A. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4658 · Cited by 100
PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways
Aeder, S. E., Martin, P. M., Soh, J., & Hussaini, I. M. (2004) · Oncogene · doi:10.1038/sj.onc.1208093 · Cited by 97
Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas
Fine, H. A., Kim, L., Royce, C., Draper, D., Haggarty, I., Ellinzano, H., Albert, P. S., Kinney, P., Musib, L. C., & Thornton, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.1504 · Cited by 96
Antiangiogenic effects of a protein kinase Cβ-selective small molecule
Teicher, B. A., Álvarez, E., Menon, K., Esterman, M. A., Considine, E. L., Shih, C., & Faul, M. M. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0386-2 · Cited by 91
Sugiyama, K., Shimizu, M., Akiyama, T., Tamaoki, T., Yamaguchi, K., Takahashi, R., Eastman, A. R., & Akinaga, S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000301)85:5<703::aid-ijc17>3.0.co;2-7 · Cited by 89
Jarvis, W. D., Povirk, L. F., Turner, A., Traylor, R. S., Gewirtz, D. A., Pettit, G. R., & Grant, S. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90484-7 · Cited by 85
A phase II study of bryostatin 1 in metastatic malignant melanoma
Propper, D., Macaulay, V. M., O'Byrne, K. J., Braybrooke, J. P., Wilner, S., Ganesan, T., Talbot, D., & Harris, A. L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.680 · Cited by 83
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder, J. A., Shields, A. F., Zalupski, M. M., Chaplen, R., Heilbrun, L. K., Arlauskas, P., & Philip, P. A. (2001) · PubMed · Cited by 82
Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.
Trenn, G., Pettit, G. R., Takayama, H., Hu‐Li, J., & Sitkovsky, M. V. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.2.433 · Cited by 78
Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Basu, A., & Lazo, J. S. (1992) · PubMed · Cited by 73
Utz, I., Hofer, S., Regenass, U., Hilbe, W., Thaler, J., Grunicke, H., & Hofmann, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570119 · Cited by 72
Fuse, E., Tanii, H., TAKAI, K., Asanome, K., Kurata, N., Kobayashi, H., Kuwabara, T., Kobayashi, S., & Sugiyama, Y. (1999) · PubMed · Cited by 72
Weichert, W., Gekeler, V., Denkert, C., Dietel, M., & Hauptmann, S. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.3.633 · Cited by 69
Dees, E. C., Baker, S. D., O’Reilly, S., Rudek, M. A., Davidson, S. B., Aylesworth, C. A., Elza-Brown, K., Carducci, M. A., & Donehower, R. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.664.11.2 · Cited by 68
Andrejauskas-Buchdunger, E., & Regenass, U. (1992) · PubMed · Cited by 67
Varga, A., Czifra, G., Tállai, B., Németh, T., Kovács, I., Kovács, L., & Bíró, T. (2004) · European Urology · doi:10.1016/j.eururo.2004.04.014 · Cited by 67
Budworth, J., Davies, R., Malkhandi, J., Gant, T. W., Ferry, D. R., & Gescher, A. J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.205 · Cited by 64
Grossman, S. A., Alavi, J. Β., Supko, J. G., Carson, K. A., Priet, R., Dorr, F. A., Grundy, J. S., & Holmlund, J. (2005) · Neuro-Oncology · doi:10.1215/s1152851703000353 · Cited by 64
Tanwell, C. S., Gescher, A. J., Bradshaw, T. D., & Pettit, G. R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560420 · Cited by 62
Koutcher, J. A., Motwani, M., Zakian, K. L., Li, X. K., Matei, C., Dyke, J. P., Ballon, D., Yoo, H. H., & Schwartz, G. K. (2000) · PubMed · Cited by 60
Millward, M. J., House, C. M., Bowtell, D. D. L., Webster, L. K., Olver, I., Gore, M. E., Copeman, M. C., Lynch, K., Yap, A., Wang, Y., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603331 · Cited by 54
Mohammad, R. M., Diwakaran, H., Maki, A., Emara, A. M., Pettit, G. R., Redman, B. G., & Al-Katib, A. M. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00037-o · Cited by 53
Thavasu, P., PROPPER, D. J., McDonald, A. C., Dobbs, N. A., Ganesan, T. S., Talbot, D., Braybrook, J., Caponigro, F., Hutchison, C., Twelves, C., et al. (1999) · PubMed · Cited by 51
Self-citationStaurosporine‐related compounds, K252a and UCN‐01, inhibit both cPKC and nPKC
Mizuno, K., Saido, T. C., Ohno, S., et al. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80254-r · Cited by 49
Jones, C. “., Clements, M. K., Wasi, S., & Daoud, S. S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050037 · Cited by 47
Green, L. J., Marder, P., RAY, C. A., Cook, C. A., Jaken, S., Musib, L. C., Herbst, R. S., Carducci, M., Britten, C. D., Basche, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2231 · Cited by 45
Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer
Lahn, M., Chen, S., Li, S., Chedid, M., Hanna, K. R., Graff, J. R., Sandusky, G. E., Ma, D., Niyikiza, C., Sundell, K. L., et al. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.032 · Cited by 42
Manni, A., Buckwalter, E. A., Etindi, R., et al. (1996) · PubMed · Cited by 38
Ritch, P. S., Rudin, C. M., Bitran, J. D., Edelman, M. J., Makalinao, A., Irwin, D. H., Lilenbaum, R., Peterson, P. M., & John, W. J. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.12.012 · Cited by 36
Protein kinase C: A key factor in the regulation of tumor cell adhesion to the endothelium
Herbert, J. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90123-e · Cited by 34
Ainsworth, P. D., Winstanley, J. H. R., Pearson, J., Bishop, H., & Garrod, D. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.027 · Cited by 31
Down‐regulation of protein kinase C‐α detected in human colorectal cancer
Suga, K., Sugimoto, I., Ito, H., & Hashimoto, E. (1998) · IUBMB Life · doi:10.1080/15216549800201552 · Cited by 29
Phase I Study of Bryostatin 1 and Gemcitabine
El-Rayes, B. F., Gadgeel, S. M., Shields, A. F., Manza, S. G., LoRusso, P. M., & Philip, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1419 · Cited by 24
Beck, J. F., Brügger, D., Brischwein, K., Liu, C., Bader, P., NIETHAMMER, D., & Gekeler, V. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01178.x · Cited by 23
Yoshikawa, N., Nakamura, K., Yamaguchi, Y., Kagota, S., Shinozuka, K., & Kunitomo, M. (2003) · Life Sciences · doi:10.1016/s0024-3205(02)02407-4 · Cited by 12
Leong, S., Camidge, D. R., Eckhardt, G., Basche, M., Musib, L. C., Darstein, C., Thornton, D., & Britten, C. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2048 · Cited by 9
Cited by
Wymann, M. P., & Schneiter, R. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2335 · Cited by 1,291
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Molecular Mechanisms and Clinical Implications of Reversible Protein S -Glutathionylation
Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A., & Shelton, M. D. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2089 · Cited by 523
Protein kinase C: poised to signal
Newton, A. C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00477.2009 · Cited by 512
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Metadata
- Authors
- Mackay, H. J., & Twelves, C. J.
- Venue
- Nature Reviews Cancer
- Published
- 2007-07
- Volume
- 7
- Issue
- 7
- Pages
- 554-562
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980814667
- Cited by
- 373
- References
- 99
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.